Bayer AG to Unveil New Phase‑III Cardiovascular, Kidney and Stroke Findings at ESC Congress 2026

Bayer AG announced today that it will present a comprehensive set of late‑breaking phase‑III data at the European Society of Cardiology (ESC) Congress in Munich, scheduled for 28 – 31 August 2026. The company’s disclosures will span three interrelated therapeutic areas—cardiovascular disease, chronic kidney disease (CKD) and stroke prevention—highlighting the firm’s strategic focus on conditions that share overlapping pathophysiology and risk factors.

Cardiovascular and Renal Outcomes with Finerenone (KERENDIA®)

Bayer will release detailed subgroup analyses of the ongoing FINERENONE‑CKD trial, a pivotal phase‑III study evaluating the mineralocorticoid receptor antagonist in patients with CKD. The new data will dissect outcomes by:

  • Diabetes status – delineating efficacy and safety in diabetic versus non‑diabetic CKD populations.
  • Hypertensive nephropathy – focusing on patients whose kidney disease is driven by hypertension.
  • Atherosclerotic cardiovascular disease (ASCVD) history – presented via the INFINITY pooled analysis, which aggregates outcomes from finerenone-treated patients with and without prior ASCVD events.

These insights are expected to refine risk‑benefit profiles, informing clinicians about the drug’s utility across a spectrum of comorbidities that frequently coexist in cardiometabolic populations.

PET Imaging for Cardiac Amyloidosis

Bayer will also present data on the investigational positron‑emission‑tomography (PET) radiotracer I‑124 evuzamitide, derived from a phase‑III trial targeting patients with suspected cardiac amyloidosis. The study aimed to evaluate the tracer’s ability to non‑invasively identify amyloid deposition in the myocardium, a condition that often masquerades as heart failure with preserved ejection fraction. By providing early diagnostic insights, this modality could accelerate therapeutic decision‑making in a disease where timely intervention is critical.

Stroke Prevention with Asundexian

The company will discuss interim results from the OCEANIC‑STROKE phase‑III trial, which investigates the direct oral anticoagulant asundexian in secondary stroke prevention. The trial examines the drug’s efficacy in reducing recurrent ischemic events while maintaining an acceptable safety profile, particularly regarding bleeding risk—a perennial challenge in anticoagulant therapy.

Strategic Implications and Market Context

Bayer’s decision to present these findings at the ESC Congress underscores the interconnected nature of cardiovascular, renal, and cerebrovascular diseases. The company’s portfolio strategy reflects several broader economic and therapeutic trends:

  1. Pneumonization of Cardiometabolic Care – Patients with CKD, diabetes, and ASCVD often require multidisciplinary management. Bayer’s data on finerenone across multiple comorbidity strata supports a holistic approach that may resonate with integrated care models gaining traction in health systems worldwide.

  2. Diagnostic Innovation as a Differentiator – The I‑124 evuzamitide trial represents a move toward precision diagnostics, an area increasingly valued by payers and clinicians seeking to reduce downstream costs associated with misdiagnosis or delayed treatment.

  3. Expanding Anticoagulant Portfolio – Asundexian’s focus on secondary stroke prevention addresses a high‑value therapeutic niche. Success in this arena could position Bayer as a contender in an anticoagulant market currently dominated by warfarin, direct oral anticoagulants (DOACs), and newer agents targeting factor Xa or thrombin.

  4. Alignment with Global Health Priorities – Cardiovascular disease remains the leading cause of death worldwide. By advancing therapeutics that intersect multiple disease states, Bayer aligns itself with global initiatives aiming to curb the rising burden of chronic kidney disease and stroke.

Conclusion

Bayer AG’s forthcoming presentations at the ESC Congress will likely shape clinical perspectives on three tightly coupled disease areas. The firm’s emphasis on rigorous, late‑stage clinical evidence across diverse patient subgroups reflects an adaptive strategy that acknowledges the complexity of modern therapeutic landscapes. As these findings are disseminated, they may influence prescribing patterns, reimbursement decisions, and future research priorities, reinforcing Bayer’s role as an influential player in the global cardiovascular, renal, and neurological markets.